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Abstract
Background: Treatment with non-steroidal anti-inflammatory drugs (NSAID) is a common component of treatment
regimens for rheumatoid arthritis (RA). Etoricoxib is a COX-2 selective NSAID that has demonstrated efficacy in the
treatment of RA at a dose of 90 mg. The current study further evaluated the efficacy of etoricoxib 60 mg and 90
mg in RA patients with active disease.
Methods: This was a 2-part, double-blind, placebo-controlled study in RA (NCT01208181). Patients were required to
have a diagnosis of RA (according to ARA 1987 revised classification criteria) and were to demonstrate symptom flare
upon discontinuation of previous NSAID treatment prior to randomization. Part I was a 6-week, placebo-controlled
period to assess the efficacy of etoricoxib 90 mg and etoricoxib 60 mg, each compared to placebo, as well as to each
other. Part II was a 6-week period to evaluate the potential benefit of dose escalation from etoricoxib 60 mg to
etoricoxib 90 mg after 6 weeks exposure to etoricoxib 60 mg in Part I compared to maintaining a steady dose of
etoricoxib 60 mg throughout Parts I and II. Primary endpoints were Disease Activity Score evaluating 28 joints and C
reactive protein level (DAS28-CRP) index and Patient Global Assessment of Pain (Pain) score (0–100 mm VAS) after 6
weeks of treatment in Part I. Adverse events were monitored throughout the study.
Results: In total, 1404 patients were randomized in a 2:7:7:8 ratio; 1228 patients completed Part I and 713 patients
continued to Part II. Both etoricoxib doses were superior to placebo on both primary efficacy endpoints (p = 0.004 for 60
mg and p = 0.034 for 90 mg for DAS28-CRP; p < 0.001 for both doses for PGAP) in Part I. Further in Part I, etoricoxib 90
mg was not significantly different from 60 mg for DAS28-CRP, but did demonstrate a small, but statistically significant
decrease in baseline PGAP score vs. 60 mg (p = 0.019). In Part II, there was no significant decrease in PGAP score after
increasing to 90 mg in subjects with inadequate pain relief on 60 mg as compared to subjects who stayed on 60 mg.
The incidence of AEs and SAEs were similar between etoricoxib 60 mg and 90 mg in both Part I and II.
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Conclusion: Both etoricoxib 90 mg and 60 mg are superior to placebo in relieving the symptoms of RA. Etoricoxib 90
mg vs 60 mg resulted in a statistically significant, though small, improvement in PGAP score, but not DAS28-CRP. Dose
escalation from 60 mg to 90 mg in pain inadequate responders did not significantly improve efficacy. These results
confirm the efficacy and tolerability of etoricoxib 90mg in patients with RA. In addition, this study demonstrated that
etoricoxib 60 mg is also efficacious and well-tolerated in RA.
Clinical Trial Registration: NCT01208181 (registered September 22, 2010).
Background
Rheumatoid arthritis (RA) is a disabling condition asso-
ciated with symptoms that ultimately lead to significant
disability. Among these symptoms, pain is a primary
complaint according to patients that most often leads
them to seek treatment [1]. Pain in chronic conditions
can have a significant impact on the lives of patients and
often includes interference in daily life and the reduction
of the ability of patients to work and engage in social
activities, thus affecting psychological wellbeing [2].
Biologic treatments targeting the immunological path-
ology of RA have greatly improved patient outcomes
and have made remission and prevention of joint
destruction possible [3, 4]. However, despite advances in
treatment with biologics, research has suggested that RA
patients can continue to experience significant levels of
pain even when underlying disease markers of RA (i.e.
DAS-28) are controlled by modern therapeutic regimens
[5, 6]. Nonsteroidal anti-inflammatory drugs (NSAIDs)
are treatments that target the cyclooxygenase (COX) 1
and 2 isozymes and are often recommended as first-line
therapy in rheumatic joint disorders [4]. NSAIDs provide
pain relief, which can greatly improve quality of life, and
may continue to be important in those patients who
continue to possess high levels of pain from RA despite
adequate disease modifying treatment [1, 7].
Etoricoxib is a COX-2 selective NSAID with high select-
ivity for COX-2 vs. COX-1 [8] that has demonstrated effi-
cacy in the treatment of pain from RA. Clinical trial data
suggest that NSAIDs such as etoricoxib can provide symp-
tomatic benefits to RA patients, complimenting the disease
modifying effects observed with biologic therapy [9]. Previ-
ous studies have evaluated several doses of etoricoxib iden-
tifying 90 mg as the optimal dose, although the 60 mg dose
has also demonstrated symptomatic improvements as
compared with placebo, particularly for pain [10–12].
Because previous studies suggest that 60 mg can
provide significant pain improvement and therefore has
some clinically meaningful effect, this study was done to
specifically evaluate the effect of etoricoxib 60 mg and
90 mg vs. placebo as well as compare both doses to each
other in RA. The potential benefit of dose escalation to
90 mg in patients who do not respond to treatment with
60 mg was also evaluated. Guidelines recommend the
use of the lowest efficacious dose of NSAIDs to provide
symptomatic treatment while mitigating potential ad-
verse experiences (AEs). Data from this study helps to
further define an additional efficacious dose of etoricoxib
for RA patients, leading to greater dosing flexibility and
an optimized benefit/risk ratio for individual patients
receiving etoricoxib.
Methods
This study (Clinical Trials Registry # NCT01208181,
Sponsor Protocol MK-0663 Protocol 107) was conducted
at 211 study centers in Argentina, Austria, Canada,
Columbia, Czech Republic, Finland, Germany, Guatemala,
India, Lithuania, Mexico, Panama, Peru, Poland, Romania,
Russia, Slovakia, South Africa, Taiwan, the United
Kingdom, and the United States. The study was initiated
in September 2010 and completed in August 2014. The
protocol for the study was approved by local institutional
review boards or ethical review committees (Additional
file 1) and was conducted according to principles of Good
Clinical Practice. Patients provided informed consent
prior to participation in the study.
Patients
Male and female patients, at least 18 years of age, with a
diagnosis of RA made at least 6 months prior to the
screening visit, who met American Rheumatology Associ-
ation (ARA) 1987 revised classification criteria, who
demonstrated a prior clinical response to NSAIDs and
who took NSAIDs on a regular basis were enrolled.
Patients on stable doses of selected non-study anti-
rheumatic therapies participated in the study (and
remained on their non-study anti-rheumatic therapy
throughout) provided that activity and flare criteria were
met following NSAID washout. Following discontinuation
(“washout”) of NSAIDs, patients must have demonstrated
sufficient disease activity defined by activity criteria and
worsening in signs and symptoms from the screening visit
(Visit 1). Flare criteria included all three of the following:
1) ≥6 tender joints and an increase in number of tender
joints of at least 20 % (or a minimum of 2 tender joints,
whichever is greater) compared to values prior to wash-
out; 2) ≥3 swollen joints and an increase in number of
swollen joints of at least 20 % (or a minimum of 2 swollen
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joints, whichever is greater) compared to the values prior
to washout; and 3) Investigator’s Global Assessment of
Disease Activity must be “fair”, poor”, or “very poor post
washout”. One of the following two criteria were also to
be met in order for patients to be randomized to study
treatment: 4) Duration of morning stiffness ≥45 min, and
an increase in duration of morning stiffness of at
least 15 min compared to results prior to washout;
OR 5) Patient’s assessment of pain >40 mm and an
increase of at least 10 mm in patient’s assessment of
pain over the value prior to washout.
Study design
This was a 2-part, double-blind, 12-week placebo-
controlled study in patients with RA. Eligible patients were
randomized at Visit 2 (randomization visit) to 1 of the 4
treatment sequences (treatment in Part I/treatment in Part
II) in a 2:7:7:8 ratio: Treatment Sequence 1 (N = 118):
placebo/patient completed the study at the end of Part I;
Treatment Sequence 2 (N = 409): etoricoxib 60 mg in Part
I/etoricoxib 60 mg in Part II; Treatment Sequence 3
(N = 409): etoricoxib 60 mg in Part I/etoricoxib 90 mg in
Part II; Treatment Sequence 4 (N = 468): etoricoxib
90 mg/patient completed the study at the end of Part I
(Fig. 1). Randomization was stratified by concomitant use
of biological disease modifying therapy (biologics) and the
proportion of concomitant biologics users was capped at
50 % of the total study population.
Efficacy parameters
The primary hypothesis was that etoricoxib 90 mg and
etoricoxib 60 mg will demonstrate superior clinical effi-
cacy compared with placebo after 6 weeks of treatment
(end of Part I), as assessed by the co-primary endpoints.
The co-primary endpoints included: 1) the time-
weighted average change from baseline in the Disease
Activity Score evaluating 28 joints using C reactive protein
(DAS28-CRP) in Part I (etoricoxib 90 mg vs. placebo and
Fig. 1 CONSORT diagram/study design
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etoricoxib 60 mg vs. placebo); and 2) time-weighted aver-
age change from baseline in Patient Global Assessment of
Pain (Pain) in Part I (etoricoxib 90 mg vs. placebo and
etoricoxib 60 mg vs. placebo). This study was to be de-
clared positive if etoricoxib 90 mg is shown to be superior
to placebo in both the DAS28-CRP and Pain (VAS).
The key secondary endpoints were time-weighted
average change from baseline in DAS28-CRP and Pain
in Part I (etoricoxib 90 mg vs. etoricoxib 60 mg), and
change from Week 6 to Week 10 and 12 in Pain (inad-
equate responders to etoricoxib 60 mg in Part I and
received etoricoxib 90 mg in Part II vs. inadequate
responders to etoricoxib 60 mg in Part I and remained
on etoricoxib 60 mg in Part II). Patients who showed
less than 50 % improvement in Pain (VAS) from baseline
at Weeks 6 were to be considered as inadequate pain
responders.
Other secondary endpoints included the proportion of
American College of Rheumatology Responder Index
criteria (20 %) (ACR20) responders in Part I, the propor-
tion of patients who discontinued due to a lack of
efficacy, time-weighted average response in Patient
Global Assessment of Response to Therapy (PGART)
(Likert 0 to 4) in Part I, and the average change from
Week 6 in PGART (Likert 0 to 4) over Weeks 10 and 12.
Safety parameters
Safety assessments included physical examinations, vital
signs, and some hematology and chemistry tests (i.e.,
hemoglobin, hematocrit, alanine aminotransferase [ALT],
aspartate transaminase [AST], and creatinine), urine and
serum ß-human chorionic gonadotropin (ß-hCG) for
women of childbearing potential, and spontaneous AE
reporting (up to 28 days [+2 days] after the last dose of
study medication). All thrombotic CV serious adverse ex-
periences (SAE) and upper GI events (such as perforation,
ulcer, or upper GI bleeding) that occurred in patients
during the study or within 28 days of its use were subject
to adjudication by a committee external to the Sponsor.
Adjudication was performed during the trial by an inde-
pendent panel of experts in cardiology, neurology, gastro-
enterology, and peripheral vascular disease, who remained
blinded to therapies.
Statistical planning and analysis
The modified intention-to-treat (mITT; consisting of all
patients who received ≥1 dose of study medication, had ≥1
post-randomization measurement, and had baseline data)
population served as the primary population for the
primary analysis as well as key secondary endpoints. The
sample size was planned to provide between 81 and 98 %
power depending on the endpoint or comparison. The 2
primary endpoints were analyzed using analysis of covari-
ance (ANCOVA). For each primary endpoint, the differ-
ence between each of the etoricoxib doses (90 mg and 60
mg) from placebo (dose-response effect) was assessed by
Tukey-Ciminera-Heyse trend test based on the least-
squares (LS) means derived from this ANCOVA (2-sided,
α = 0.05). An etoricoxib dose was declared superior to
placebo if it demonstrated significantly (p ≤ 0.05) greater
efficacy than placebo on both of these endpoints. For the
key secondary endpoints, Hochberg’s procedure was
applied for determining the significance of treatment
Fig. 2 Co-primary endpoints (mITT population). 'Patient Global Assessment of Pain was measured on a 0- to 100-mm VAS, with a lower value
representing a better response. DAS28-CRP ranges from 0 to 10, with lower scores representing a better response. LS = Least-Squares;
CI = Confidence Interval
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differences (etoricoxib 90 mg vs. etoricoxib 60 mg) for
these 2 endpoints starting with α = 0.05, (2-sided).
Patients with less than 50 % improvement in Pain
(VAS) score from baseline to Week 6 are defined as
inadequate responders. For the average change from
Week 6 in Pain (VAS) over Weeks 10 and 12, among
pain inadequate responders in Part I, the difference
between the etoricoxib 60 mg/90 mg and etoricoxib 60
mg/60 mg treatment sequences were compared using an
ANCOVA. The benefit of etoricoxib dose increase from
60 mg (in Part I) to 90 mg (in Part II) was indicated if
the nominal p-value (without multiplicity adjustment)
for the difference in LS means was ≤0.20 (2-sided) in
favor of the 90 mg dose (alpha level agreed to in consulta-
tions with EU regulatory authorities during the planning
of the study). To control the experiment-wise Type I error
rate in Part I of the study, the primary endpoints and the
first key secondary endpoint in Part I were tested sequen-
tially. No multiplicity adjustments were made for this key
secondary endpoint.
To evaluate the consistency of treatment effects, post-
hoc analyses were performed separately for subgroups
defined by ≤ or > median values for Pain (VAS), DAS28-
CRP, Tender Joint Count (68 joints), and Swollen joint
Count (66 joints).
For pre-specified AEs of interest, p-values and/or 95 %
CI’s were provided using the Miettinen and Nurminen
method for treatment group comparisons. All other AEs
were summarized with counts and percentages.
Results
Patients
Of the 1404 patients who were randomized, 83.5 % were
female and the mean age was 53.8 years. The mean dur-
ation of rheumatoid arthritis (RA) was 5.6 years and ranged
from less than 1 year to 36 years. At baseline, 235, 925, and
244 patients were American Rheumatology Association
(ARA) Functional Class I, II, or III, respectively. There were
no clinically meaningful differences between the treatment
groups for these or any other baseline disease-related
characteristics (Table 1). In Part I, 118, 818, and 468 pa-
tients received placebo, etoricoxib 60 mg, and etoricoxib 90
mg, respectively. There were 1228 patients who completed
Part I (87 %) with the most common reasons for discon-
tinuation due to lack of efficacy and adverse experiences
(Fig. 1). There were 713 patients who entered Part II with









n (%) n (%) n (%) n (%)
Gender
Female 100 (84.7) 677 (82.8) 395 (84.4) 1172 (83.5)
Age (Years)
Mean (SD) 53.6 (11.0) 53.8 (11.9) 54.0 (12.3) 53.8 (12.0)
Min-Max Age 27 – 80 18 – 83 19 – 84 18 – 84
Race
White 85 (72.0) 626 (76.5) 348 (74.4) 1059 (75.4)
Asian 16 (13.6) 93 (11.4) 55 (11.8) 164 (11.7)
Multi-racial 10 (8.5) 74 (9.0) 42 (9.0) 126 (9.0)
Black 4 (3.4) 17 (2.1) 12 (2.6) 33 (2.4)
Other 3 (2.5) 8 (1.0) 11 (2.4) 22 (1.6)
Duration of RA (Years)
Mean (SD) 4.2 (4.3) 5.7 (6.7) 5.8 (6.5) 5.6 (6.5)
ARA Functional Class
Class I 18 (15.3) 138 (16.9) 79 (16.9) 235 (16.7)
Class II 76 (64.4) 535 (65.4) 314 (67.1) 925 (65.9)
Class III 24 (20.3) 145 (17.7) 75 (16.0) 244 (17.4)
Biologics User 16 (13.6) 113 (13.8) 64 (13.7) 193 (13.7)
Methotrexate User 43 (36.4) 285 (34.8) 170 (36.3) 498 (35.5)
Low-dose Corticosteroid User 25 (21.2) 208 (25.4) 126 (26.9) 359 (25.6)
DMARD User 56 (47.5) 363 (44.4) 219 (46.8) 638 (45.4)
DMARD or Corticosteroid 61 (51.7) 425 (52.0) 247 (52.8) 733 (52.2)
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350 continuing on 60 mg and 363 switched to etoricoxib
90 mg; 677 of these patients completed Part II (95 %).
Efficacy
Etoricoxib 60 mg and 90 mg vs. placebo
Improvements in the primary endpoint of time-weighted
average change from baseline DAS28-CRP score were
significantly greater in the etoricoxib 90 mg and etori-
coxib 60 mg groups compared with the placebo group
(p = 0.034 and p = 0.004 vs. placebo, respectively) over 6
weeks of treatment in Part I in patients included in the
primary mITT population (Fig. 2).
Improvements in the primary endpoint of time-
weighted average change from baseline Pain score were
significantly greater in the etoricoxib 90 mg and etori-
coxib 60 mg groups compared with the placebo group
(p < 0.001 for both treatments vs. placebo) over 6 weeks
of treatment in Part I. The treatment difference from
placebo for etoricoxib 90 mg, but not 60 mg, met
the −10 mm MCID pre-specified in the protocol
(Fig. 2).
Results for secondary endpoints are provided in Table 2
and 3. The proportions of ACR20 responders in the etori-
coxib 90 mg and etoricoxib 60 mg groups were greater than
those in the placebo group (nominal p < 0.001 and nominal
p = 0.017, respectively). The time-weighted average re-
sponse PGART score in the etoricoxib 90 mg and etori-
coxib 60 mg groups was greater than that for the placebo
group (nominal p < 0.001 and nominal p < 0.001, respect-
ively) over 6 weeks of treatment in Part I. The etoricoxib 90
mg and etoricoxib 60 mg groups had smaller proportions
of patients who discontinued due to lack of efficacy com-
pared with the placebo group ; 2.3 % of etoricoxib 90 mg
patients and 3.8 % of etoricoxib 60 mg patients discontin-
ued due to lack of efficacy vs. 13.5 % of placebo patients
(nominal p < 0.001 and nominal p < 0.001, respectively). Re-
sults for additional endpoints such as Tender Joint Counts,
Swollen Joint Counts, Patient and Investigator Assessments
of Disease Activity, Health Assessment Questionnaire, and
C-Reactive Protein were generally similar to results for the
primary and secondary endpoints (Additional file 2: Table
S1).
Etoricoxib 60 mg vs. Etoricoxib 90 mg
For the comparison of etoricoxib 60 mg and 90 mg, the
results of hypothesis testing showed no statistically
significant difference between the etoricoxib 90 mg
group and the etoricoxib 60 mg group in the DAS28-CRP
co-primary endpoint (p = 0.730). For the co-primary end-
point of Pain, etoricoxib 90 mg led to statistically signifi-
cantly lower Pain scores compared with etoricoxib 60 mg
(p = 0.019). For the secondary endpoint of the proportion
of ACR20 responders, the etoricoxib 90 mg group had a
greater proportion of responders than that in the
etoricoxib 60 mg group (nominal p = 0.043). There was no
difference between the etoricoxib 90 mg group and the
etoricoxib 60 mg group in the time-weighted average
response PGART score. The proportion of patients who
discontinued due to lack of efficacy in the etoricoxib 60
mg group and the 90 mg group was similar (Table 2).
In Part II, there was no evidence of incremental benefit
with increasing the dose from 60 mg to 90 mg among inad-
equate pain responders who started on etoricoxib 60 mg in
Part I and increased to etoricoxib 90 mg in Part II, versus
remaining on etoricoxib 60 mg, according to the time-
weighted change in Pain, PGART, and DAS28-CRP. Results
for other, tertiary endpoints such as Tender Joint Counts,
Swollen Joint Counts, Patient and Investigator Assessments
of Disease Activity, Health Assessment Questionnaire, and
C-Reactive Protein were generally similar to results for
Pain, PGART, and DASE28-CRP (Additional file 2: Table
S2).
Post-hoc analyses of baseline subgroups
Across all four endpoints (i.e., Pain, DAS28-CRP, Tender
Joint Counts, and Swollen Joint Counts), greater im-
provement was observed with etoricoxib treatment vs.
placebo in those subjects with higher baseline scores
when compared with those subjects with lower baseline
scores (cutoffs based on median baseline values). When
comparing the two doses, the 90 mg dose demonstrated
greater improvement of scores compared with the 60
mg dose in subjects who had higher baseline scores
(Fig. 3).
Safety and tolerability
In Part I, AEs occurred in 30 (25 %), 248 (30 %), and 168
(36 %) patients in the placebo, etoricoxib 60 mg, and etori-
coxib 90 mg groups, respectively. There were 9 patients
with serious AEs: 7 (0.9 %) in the etoricoxib 60 mg group
and 2 (0.4 %) in the etoricoxib 90 mg group. There were no
deaths in this study. Additionally, there were 55 patients
who discontinued due to clinical AEs: 4 (3.4 %), 27 (3.3 %),
and 24 (5.1 %) in the placebo, etoricoxib 60 mg, and etori-
coxib 90 mg groups, respectively. The most commonly re-
ported AE was headache (3.1 to 5.1 % of patients) (Table 4).
In Part II, there were 67 (19 %) and 89 (25 %) patients
with AEs in the group of patients who continued on
etoricoxib 60 mg in Part II and the group who received
etoricoxib 90 mg in Part II. There were 9 patients with
serious AEs: 4 (1.1 %) on etoricoxib 60 mg and 5 (1.4 %)
on etoricoxib 90 mg). Discontinuations due to AEs
occurred in 5 (1.4 %) patients on etoricoxib 60 mg and 7
(1.9 %) patients on etoricoxib 90 mg. The most
commonly reported AE was nasopharyngitis (2.3 to
2.5 % of patients) (Table 5).
Prespecified AEs of interest (i.e., gastrointestinal or
renovascular AEs) were similar among the treatment
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Table 2 Summary of primary and secondary efficacy endpoints during part I (6 weeks of treatment)
Placebo Etoricoxib 60 mg LS Mean Difference
vs. Placebo; p-valuea,b
Etoricoxib 90 mg LS Mean Difference vs.
Placebo; p-value
LS Mean Difference Between






- 1.10 (-1.29, -0.90) - 1.39(-1.48, -1.30) -0.29 (-0.49, -0.09);
p = 0.004








- 20.26 (-24.04, -16.48) - 28 .25 (-30.05, -26.44) -7.99 (-11.85, -4.13);
p < 0.001








41/111 (36.94) 377/769 (49.02) 12.09 (2.52, 21.66);
p = 0.017









2.00 (1.83, 2.18) 2.46 (2.38, 2.55) 0.46 (0.28, 0.64);
p < 0.001









15/111 (13.51) 29/769 (3.77) -9.74 (-16.24, -3.24);
p < 0.001




ap-values for primary endpoints were adjusted for multiplicity; statistical significance is achieved if p ≤ 0.05













groups in both Part I and Part II. There were 2 cases of
confirmed/adjudicated thromboembolic CV events
during the study (both in the etoricoxib 60 mg Part I/90
mg Part II group during Part II of the study). These in-
cluded an acute myocardial infarction and an ischemic
stroke due to cardiac thrombus. There were 3 cases of
confirmed/adjudicated GI events during the study (all in
the etoricoxib 60 mg group during Part I). None of the
events had an adjudication outcome of confirmed upper
GI bleed.
Discussion
This study was done in order to further explore dos-
ing options for patients with RA who respond to
etoricoxib. In order to minimize the risk of AEs, the
use of the lowest dose of an NSAID, such as etori-
coxib, that achieves adequate symptomatic control of
RA symptoms is recommended. This is particularly
important in a population, such as RA patients, who
may be on multiple medications and need treatment
for chronic pain. In a previously reported dose ran-
ging study, etoricoxib 90 mg demonstrated statisti-
cally significant improvement vs. placebo in the
primary endpoint of the proportion of patients
achieving an ACR20 response, whereas etoricoxib 60
mg only demonstrated a numerical improvement that
approached statistical significance [12]. However,
both the 90 mg and 60 mg doses of etoricoxib pro-
vided statistically significant improvement for the
treatment of pain. The current trial was conducted,







N (%) with AEs 30 (25.4) 248 (30.3) 168 (36.0)
N (%) with AEs determined by the investigator to be drug related 8 (6.8) 64 (7.8) 59 (12.4)
N (%) with serious AEs 0 (0.0) 7 (0.9) 2 (0.4)
N (%) who discontinued due to AEs 4 (3.4) 27 (3.3) 24 (5.1)
Most Common AEs (incidence >2 % in one or more treatment groups)
Upper abdominal pain 2 (1.7) 12 (1.5) 11 (2.4)
Nausea 0 (0.0) 19 (2.3) 5 (1.1)
Peripheral edema 0 (0.0) 8 (1.0) 10 (2.1)
Nasopharyngitis 1 (0.8) 14 (1.7) 14 (3.0)
Blood pressure increased 2 (1.7) 10 (1.2) 13 (2.8)
Headache 6 (5.1) 25 (3.1) 17 (3.6)
Hypertension 0 (0.0) 20 (2.4) 15 (3.2)
Prespecified AEs of Interest
Hypertension-related AEsa 2 (1.7) 34 (4.2) 26 (5.6)
Discontinuation due to hypertension-related AEs 2 (1.7) 3 (0.4) 11(2.4)
Edema-related AEsb 0 (0.0) 8 (1.0) 10 (2.1)
Discontinuation due to edema-related AEs 0 (0.0) 0 (0.0) 2 (0.4)
Congestive heart failure, pulmonary edema, or cardiac failure 0 (0.0) 0 (0.0) 0 (0.0)
aHypertension-related AEs included development of hypertension or worsening of preexisting hypertension
bEdema-related AEs included edema, lower extremity edema, and peripheral edema
Table 3 Summary of secondary endpoints during part II among inadequate responders from part I
Etoricoxib 60 mg
(Part I)/60 mg (Part II)
Etoricoxib 60 mg
(Part I)/90 mg (Part II)
LS Mean Difference Between Etoricoxib
60 mg/90 mg vs. Etoricoxib 60 mg/60 mg; p-valuea
LS Mean Change from Week 6 in PGAP over
Weeks 10 and 12
−11.96 (−14.96, −8.97) −10.35 (−13.32, −7.39) 1.61 (−0.49, 3.71); p = 0.327
LS Mean Change from Week 6 in PGART over
Weeks 10 and 12
0.33 (0.19, 0.46) 0.24 (0.10, 0.37) −0.09 (−0.18, 0.00); p = 0.215
LS Mean Change from Week 6 in DAS28-CRP
over Weeks 10 and 12
−0.35 (−0.51, −0.18) −0.39 (−0.55, −0.23) −0.05 (−0.22, 0.13); p = 0.611
ap-values for secondary endpoints were not adjusted for multiplicity and are therefore nominal; statistical significance cannot be inferred from p-values for
these endpoints
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therefore, to further explore the treatment effect of
the 60 mg and 90 mg dose in RA patients with ac-
tive disease.
In this study, both etoricoxib 60 mg and 90 mg were
superior to placebo for both the co-primary endpoints of
DAS28-CRP and PGAP. These results confirm previ-
ously reported studies that show efficacy of 90 mg in the
treatment of RA and the previous dose ranging study
that showed that 60 mg also provided significant im-
provement in the treatment of pain vs. placebo in pa-
tients with RA [11, 12]. When compared with each
other, there was no significant difference between the
etoricoxib 90 mg dose and 60 mg dose for the co-
primary endpoint of DAS28-CRP. For the other co-
primary endpoint of PGAP that specifically evaluated
pain, etoricoxib 90 mg was statistically significantly su-
perior to etoricoxib 60 mg. However, in patients who
had an inadequate response to treatment with etoricoxib
60 mg after 6 weeks, switching to the 90 mg dose did
not significantly improve the pain scores.
The use of NSAIDs such as etoricoxib remains an im-
portant part of the treatment of RA. Despite widespread
adoption of biologic DMARDs with their ability to halt
disease progression and provide radiographic improve-
ment in the last decade, the use of agents that control
pain has persisted [5, 6]. A previous analysis demon-
strated that etoricoxib provided important pain relief in
Fig. 3 Treatment differences by baseline median subgroups (60 mg vs. 90 mg) for time-weighted change from baseline in efficacy endpoints over
6 weeks in Part I







N (%) with AEs 67 (19.1) 89 (24.5)
N (%) with AEs determined by the
investigator to be drug related
15 (4.3) 16 (4.4)
N (%) with serious AEs 4 (1.1) 5 (1.4)
N (%) who discontinued due to AEs 5 (1.4) 7 (1.9)
Most Common AEs (incidence >2 %
in one or more treatment groups)
Nasopharyngitis 8 (2.3) 9 (2.5)
Prespecified AEs of Interest
Hypertension-related AEs 8 (2.3) 7 (1.9)
Discontinuation due to
hypertension-related AEs
0 (0.0) 0 (0.0)
Edema-related AEs 1 (0.3) 2 (0.6)
Discontinuation due to
edema-related AEs
0 (0.0) 0 (0.0)
Congestive heart failure,
pulmonary edema, or cardiac failure
0 (0.0) 0 (0.0)
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patients with RA who continued to have pain despite
biologic DMARD treatment and/or treatment with corti-
costeroids [9]. Therefore pain relief in RA remains an
additional important treatment goal in spite of advances
in disease modifying therapy.
These results show that the etoricoxib 60 mg dose is
an effective and viable option in the treatment of RA
and can improve pain from RA and DAS28-CRP scores
while minimizing the drug dose. The variability in
patient pain responses is highlighted in post-hoc ana-
lyses that evaluated patients with greater baseline sever-
ity vs. those with lower baseline severity. In patients
with higher baseline scores, there was a greater numer-
ical degree of improvement and a larger difference in
effect between the 60 mg and 90 mg doses, particularly
for the Pain endpoint. Previous research in acute pain
models have demonstrated that the evaluation of
patients who experience greater levels of pain can better
differentiate the efficacy of analgesic medications [13].
These data show that the availability of multiple doses of
etoricoxib may be advantageous for patients who experi-
ence severe RA symptoms and who respond to etoricoxib
in a dose-dependent manner. Greater improvements in
patients with greater baseline symptom severity were seen
in the endpoint evaluating pain as well as DAS28-CRP,
Swollen Joint Counts, and Tender Joint Counts.
There have recently been efforts to simplify the quan-
tification of efficacy through the identification of minim-
ally clinically important differences [14]. In this study,
we prespecified a −0.5 unit difference from placebo in
DAS28-CRP and a −10 mm difference from placebo in
Pain. The −0.5 unit difference from placebo for DAS28-
CRP is based on previous research with biologic agents
[15]. Whether or not this benchmark applies to
treatment with NSAIDs is uncertain, but was used as a
starting point in this study. The MCID of −10 mm
difference from placebo for Pain was established based
on the work of the Initiative on Methods Measurement
and Pain Assessment in Clinical Studies (IMMPACT),
which suggested that a 10 % change from baseline with
regard to pain scores represented the lower boundary of
clinical importance [16]. However, since the develop-
ment of an MCID for pain was based on separating
active treatment from placebo and not separating active
treatment arms, it is possible that patients experience
meaningful clinical improvement at the 90 mg vs. 60 mg
dose at a smaller difference in pain score than that
specified by the MCID. The assignment of MCIDs for
pain relief in RA patients is also problematic because
literature is scarce for RA specifically. In this study,
etoricoxib did not reach −0.5 unit difference from
placebo for the DAS28-CRP endpoint. Etoricoxib 90 mg,
but not etoricoxib 60 mg, reached the −10 mm differ-
ence for Pain.
The primary endpoint, DAS28-CRP, was developed to
measure effectiveness for DMARDs and is therefore
commonly used in RA trials, however it may not be the
best tool for evaluating NSAID efficacy because NSAIDs
in general do not have an effect on CRP in RA patients
[17]. While NSAIDs may show an effect on tender joint
counts, DAS28-CRP results may be blunted due to a lack
of effect on CRP, leading to smaller treatment effects.
NSAIDs have been associated with safety and tolerabil-
ity risks, particularly gastrointestinal, renovascular, and
cardiovascular risks, which necessitates an individualized
approach to treat pain with these medications [18–20].
This study did not identify new AEs and was consistent
with previous research on etoricoxib in the treatment of
RA. The etoricoxib groups had a low proportion of
patients with serious AEs while the placebo group had
no serious AEs. There were dose-related incidences of
hypertension-related AEs with the largest proportion of
patients with these AEs occurring in the 90 mg group.
Renovascular AEs such as hypertension have previously
been associated with etoricoxib [21].
Previous studies have identified a risk of thrombotic
CV events and GI ulcers and bleeding with the use of
NSAIDs [20, 22]. These events are rare and require
large outcome studies to properly identify to assess
the risk of an individual NSAID. The CV risk of
etoricoxib, a COX-2 selective NSAID, was evaluated
compared with the traditional NSAID, diclofenac, in a
large outcome trial; both medications were found to
have a similar CV risk profile. Additionally, the GI
profile of etoricoxib and diclofenac were compared
and demonstrated that etoricoxib was associated with
fewer uncomplicated upper GI events vs. diclofenac,
but a similar incidence of complicated events. CV and
GI events were rare with a similar incidence between
treatment groups in this study.
This study was limited in that it was not designed nor
powered to properly evaluate rare AEs of interest for
NSAIDs such as CV and GI AEs. Additionally, this trial
enrolled patients who previously demonstrated a response
to NSAID treatment and who exhibited a flare of symp-
toms upon withdrawal of previous NSAID therapy. Our
study included NSAID responders and used flare criteria in
order to address specific objectives regarding potential dif-
ferences in efficacy between to different doses of etoricoxib.
This is a common design element in NSAID trials and
recent research has shown that flare designs do not affect
the treatment effect sizes observed in clinical trials com-
pared with non-flare designs [23].
Conclusion
In summary, in this study, both etoricoxib 90 mg and 60
mg once daily were superior to placebo in relieving the
signs and symptoms of RA. Furthermore, etoricoxib 90 mg
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once daily compared with 60 mg once daily resulted in a
statistically significant, though small, improvement in Pa-
tient Global Assessment of Pain (PGAP), but not Disease
Activity Score (DAS28-CRP). Inadequate pain responders
on etoricoxib 60 mg did not benefit from dose escalation to
etoricoxib 90 mg. Both etoricoxib 90 mg and 60 mg were
well tolerated confirming that etoricoxib 90 mg and 60 mg
once daily are safe and effective treatment regimens for re-
lieving the signs and symptoms of RA. Importantly, these
data provide evidence that etoricoxib 60 mg is an additional
efficacious etoricoxib dose that can provide clinicians with
increased dosing flexibility to treat individual patient needs.
The sum of the evidence suggests that for most patients
with RA, the minimum clinically effective dose of etori-
coxib is 60 mg once daily. However, in patients with higher
baseline pain, etoricoxib 90 mg may provide better symp-
tom control than 60 mg. A range of effective doses (60 or
90 mg) has now been described, which will allow for more
individualized treatment recommendations by healthcare
providers, consistent with dosing regimens of other
NSAIDs used in the management of RA.
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